• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies

  • Print
  • Share
  • E-mail
-

Post-Approval Studies

  • In January 2005, the oversight responsibility of the Post-Approval Studies Program was transferred to the Division of Epidemiology (DEPI) of the Office of Surveillance and Biometrics (OSB)/Center for Devices and Radiological Health (CDRH).
  • The CDRH Post-Approval Studies Program encompasses design, tracking, oversight, and review responsibilities for studies mandated as a condition of approval of a premarket approval (PMA) application, protocol development product (PDP) application, or humanitarian device exemption (HDE) application. The program helps ensure that well-designed post-approval studies (PAS) are conducted effectively and efficiently and in the least burdensome manner.
  • CDRH has established an automated, internal tracking system that efficiently identifies the reporting status of active PAS studies ordered since January 1, 2005 based on study timelines incorporated in study protocols and agreed upon by the CDRH and applicants. This system represents CDRH's effort to ensure that all PAS commitments are fulfilled in a timely manner.
  • In addition, CDRH launched this publicly available webpage to keep all stakeholders informed of the progress of each PAS. The webpage displays general information regarding each PAS, as well as the overall study status (based on protocol-driven timelines and the adequacy of the data) and the applicant's reporting status for each submission due.

Links

Contact Information

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Show All Studies
Suggest Enhancement / Report Issue | Export to ExcelExport to Excel
General
Application Number P110033
Current Protocol Accepted 10/22/2013
Study Name VOLUMA-003 Repeat Treatment Study
Study Status Progress Adequate
General Study Protocol Parameters
Study Design Other Study Design
Study involve follow-up of premarket cohort (Y/N) Yes
Data Source Other Data Source
Comparison Group No Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description Statistical analysis of data collected in the premarket study
Study Population Description Subjects who enrolled in the premarket study and received repeat treatment
Sample Size At least 167 modified intent-to-treat (mITT) subjects.
Data Collection Safety Endpoints include: presence, severity, location (zygomaticomalar region, anteromedial cheek, and/or

submalar region), and duration of   show the rest ...
Followup Visits and Length of Followup 12 months after repeat treatment

1, 3, 6, 9, and 12 months after repeat treatment



VOLUMA-003 Repeat Treatment Study Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Reporting Status
six month report 04/22/2014 04/18/2014 On Time
one year report-final report 10/22/2014 09/29/2014 On Time
18 month report 04/22/2015    
two year report 10/22/2015    
three year report 10/21/2016    
four year report 10/21/2017    
five year report 10/21/2018    

Show All Studies

-
-